CAVA Group, Inc. (NYSE:CAVA) experienced a sharp decline on Monday, with shares falling 7.7% to close at $63.51. The drop erased approximately $631 million from the company's market capitalization, representing more than half of its projected fiscal 2025 revenue. The sell-off was the steepest among fast-casual restaurant stocks tracked, underscoring how a premium valuation can amplify market reactions to negative news.
FDA Lettuce Investigation Weighs on Sentiment
The decline followed an ongoing investigation by the U.S. Food and Drug Administration into a lettuce-related outbreak. Although the FDA has retracted a positive test result as a false positive, the investigation remains active. Notably, the FDA's advisory did not mention CAVA, and Barron's reported no verified link between the chain and the outbreak. The probe continues to focus on shredded iceberg lettuce served at Taco Bell, a Yum! Brands (NYSE:YUM) restaurant. According to the advisory, 1,644 individuals have fallen ill, 94 have been hospitalized, and there have been no fatalities.
Valuation Concerns Come to the Fore
Monday's sharp sell-off highlights the vulnerability of CAVA's stock, which trades at a price-to-earnings ratio of 122.1x. This multiple is over four times that of Chipotle Mexican Grill (NYSE:CMG) at 29.6x, and significantly higher than peers such as Sweetgreen (NYSE:SG) at 55.4x and Shake Shack (NYSE:SHAK) at 58.1x. Such a high valuation leaves little room for error; any sign of traffic disruption can lead to outsized losses.
The broader context suggests the decline may reflect a broader traffic disruption rather than an issue unique to CAVA. However, the high multiple magnifies the impact of any negative news on the stock price.
Recent Performance and Analyst Upgrades
Prior to Monday's drop, CAVA shares had already fallen 4.6% last week, sliding from $72.18 to $68.85. As of Monday, the stock had extended its loss from July 10 to 12.0%. This decline followed an upgrade from Morgan Stanley (NYSE:MS) analyst Brian Harbour, who raised his price target to $90 from $86, citing increased traffic, unit expansion, and strong results at new locations.
CAVA reported first-quarter revenue of $434.4 million, up 32.2% year-over-year. Comparable restaurant sales climbed 9.7%, supported by a 6.8% increase in traffic. The company's operating metrics continue to outperform most peers in the restaurant sector. Chief Executive Brett Schulman stated the results demonstrated the “structural strength of our business.” CAVA launched 20 new restaurants in the quarter.
Outlook and Risks
Management increased its 2026 outlook to 75 to 77 new restaurant openings. Same-restaurant sales are projected to grow between 4.5% and 6.5%, with adjusted EBITDA guided at $181 million to $191 million. CAVA's investor calendar lists no upcoming events through Friday, making FDA updates the most likely near-term catalyst.
Risks include wider spending cuts at restaurants or additional outbreak reports that may reduce visitor numbers. The 122x price multiple also makes any earnings shortfall more expensive for shareholders. Investors will be watching for any developments in the FDA investigation that could further impact CAVA's traffic and stock performance.
